Post-marketing Surveillance (PMS) of GlaxoSmithKline Biologicals' 10-valent Pneumococcal Conjugate Vaccine (Synflorix) When Administered to Healthy Infants and Children According to the Prescribing Information in Sri Lanka
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 06 Sep 2013
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 06 Sep 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 15 Mar 2013 Planned End Date changed from 1 Jan 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 15 Mar 2013 Planned initiation date (1 Apr 2013) added as reported by ClinicalTrials.gov.